Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$158.00 USD

158.00
1,925,520

+0.04 (0.03%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $157.92 -0.08 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

Sarepta Therapeutics, Inc. [SRPT]

Reports for Purchase

Showing records 401 - 420 ( 665 total )

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 401

05/25/2016

Daily Note

Pages: 4

FDA Has Not Said No to Sarepta''s Eteplirsen; Reiterate NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 402

05/09/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 403

05/05/2016

Company Report

Pages: 6

Eyes on PDUFA Date as Sarepta Reports 1Q16; Reiterate NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 404

04/26/2016

Daily Note

Pages: 6

Despite a Groundswell of Hope, Door Appears Shut on Eteplirsen for Now; Reiterate NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 405

04/22/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 25

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 406

04/21/2016

Company Report

Pages: 7

Downgrading to NEUTRAL; FDA Doubles Down on No; Stepping to the Sidelines due to Regulatory Risk; PT to $14

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 407

04/05/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 408

04/01/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 4

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 409

03/28/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 410

03/21/2016

Industry Report

Pages: 4

Lifesciences Review: Down but not out

Provider: HYBRIDAN LLP

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 411

03/09/2016

Company Report

Pages: 5

Sarepta Announces Consolidation Plans but Still No News on an Advisory Panel; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 412

03/02/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 413

02/26/2016

Company Report

Pages: 5

Waiting on FDA as Sarepta Reports 4Q15 Results; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 414

02/10/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 415

02/08/2016

Company Report

Pages: 6

Waiting is the Hardest Part - Continued Uncertainty Overshadows Eteplirsen; Reiterating OUTPERFORM but Lowering PT to $32

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 416

02/08/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 417

02/05/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 418

02/03/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 419

02/02/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 420

02/01/2016

Daily Note

Pages: 6

Curiouser and Curiouser - A Deeper Look into the Eteplirsen Briefing Documents; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party